The object of this project is to analyze in depth the expression of regulatory phenotypes of normal and leukemic human progenitor cells, to correlate regulatory phenotype with the growth behavior of progenitor cells in vitro, and to define mechanisms for altering abnormal phenotypes in order to modify abnormal cell differentiation. A unique limited suspension culture system with prostaglandin E?1? (PGE?1?) will be used to modulate CFU-GM HLA-DR expression and investigate its implication in the control of CFU-GFM proliferation. A multifaceted in-depth study of specific modulation of antigenic expression and regulatory responsiveness in a strategy designed to restore a normal pattern of proliferation and differentiation offers a mechanism for control of leukemic cell proliferation and suggests an alternative approach to therapy. Evidence indicates that the disordered regulation observed in patients with CML can be restored by modulation of CFU-GM Ia-antigen following exposure to PGE. Analysis of normal, accessory cell function indicates a role for T lymphocytes in the control of CFU-GM cell cycle and Ia antigen expression. The mechanism(s) of action of T cells in normal and abnormal human myelopoiesis will be investigated. (MB)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA033225-05
Application #
3171181
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1985-09-01
Project End
1988-07-31
Budget Start
1986-08-01
Budget End
1987-07-31
Support Year
5
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Ottmann, O G; Abboud, M; Welte, K et al. (1989) Stimulation of human hematopoietic progenitor cell proliferation and differentiation by recombinant human interleukin 3. Comparison and interactions with recombinant human granulocyte-macrophage and granulocyte colony-stimulating factors. Exp Hematol 17:191-7
Nocka, K H; Ottman, O G; Pelus, L M (1989) The role of marrow accessory cell populations in the augmentation of human erythroid progenitor cell (BFU-E) proliferation by prostaglandin E. Leuk Res 13:527-34
Pelus, L M (1989) Blockade of prostaglandin biosynthesis in intact mice dramatically augments the expansion of committed myeloid progenitor cells (colony-forming units-granulocyte, macrophage) after acute administration of recombinant human IL-1 alpha. J Immunol 143:4171-9
Pelus, L M (1989) Modulation of myelopoiesis by prostaglandin E2: demonstration of a novel mechanism of action in vivo. Immunol Res 8:176-84
Ottmann, O G; Pelus, L M (1988) Differential proliferative effects of transforming growth factor-beta on human hematopoietic progenitor cells. J Immunol 140:2661-5
Ottmann, O G; Nocka, K H; Moore, M A et al. (1988) Differential expression of class II MHC antigens in subpopulations of human hematopoietic progenitor cells. Leukemia 2:677-86
Pelus, L M; Gentile, P S (1988) In vivo modulation of myelopoiesis by prostaglandin E2. III. Induction of suppressor cells in marrow and spleen capable of mediating inhibition of CFU-GM proliferation. Blood 71:1633-40
Nocka, K H; Pelus, L M (1988) Cell cycle specific effects of deferoxamine on human and murine hematopoietic progenitor cells. Cancer Res 48:3571-5
Pelus, L M; Vadhan-Raj, S (1988) Modulation of responsiveness of chronic myelogenous leukemia granulocyte-macrophage colony-forming cells to growth regulation following in vivo treatment with recombinant gamma-interferon. Am J Hematol 28:21-6
Gentile, P S; Pelus, L M (1988) In vivo modulation of myelopoiesis by prostaglandin E2. IV. Prostaglandin E2 induction of myelopoietic inhibitory activity. J Immunol 141:2714-20

Showing the most recent 10 out of 17 publications